Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non‐small cell lung cancer (NSCLC) with an extremely poor prognosis making it a therapeutic challenge. However, the development of genetic variation molecular diagnosis and targeted agents has brought the treatment of such malignancies to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaomeng, Cao, Jie, Du, Weijiao, Zhang, Weihong, Cao, Shui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299264/
https://www.ncbi.nlm.nih.gov/pubmed/34322251
http://dx.doi.org/10.1002/ccr3.4487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299264/
https://www.ncbi.nlm.nih.gov/pubmed/34322251
http://dx.doi.org/10.1002/ccr3.4487

Ejemplares similares